Lactic acid bacteria with anti-hyperuricemia ability: Screening in vitro and evaluating in mice

Hyperuricemia has become the increasing public health burden, which is a risk factor for gout, chronic kidney, cardiovascular diseases and diabetes. Lactic acid bacteria have been attracting considerable interest for the safe and effective treatment of hyperuricemia in recent years. In this study, Limosilactobacillus fermentum NCUH003018, Limosilactobacillus reuteri NCUH064056 and Lactobacillus gasseri NCUH066006 were preliminarily selected from sixty strains of lactic acid bacteria isolated from infant feces and fermented vegetables, and showed the ability of efficient degradation of inosine and guanosine, inhibition of xanthine oxidase activity, the tolerance to acid and bile salt, adhesion to epithelium cells, antibacterial activity, and antibiotic susceptibility in vitro. Then hyperuricemia mice model was established by high-yeast diet and intraperitoneal injection of potassium oxonate to analyze the uric acid-lowering effect of the three Lactobacillus in vivo. The results showed that Limosilactobacillus fermentum NCU003018 was the most effective in lowering uric acid level in mice, which prompted the decrease of serum uric acid by 30.77% compared with hyperuricemia model group. Therefore, the Limosilactobacillus fermentum NCU003018 is considered as a probiotic with anti-hyperuricemia ability, which could be used as a promising candidate in preventing and treating hyperuricemia, and the uric-acid lowering mechanism merits further investigation.